[ad_1]
BOSTON, July 16, 2019 / PRNewswire / – Diabetes Mellitus, commonly known as diabetes, is a condition characterized by high blood sugar. In a healthy individual, the sugar in the blood is regulated by insulin, a hormone produced by pancreatic islet beta cells. When blood sugar is not regulated, the individual is at risk for short-term health emergencies such as hypoglycemia and hyperglycemia. Long-term complications of diabetes include neuropathy, blindness, even wounds that do not heal and often result in amputation. Diabetes is a very expensive disease, 90% of which is due to the side effects of the disease. As such, it is important to develop technologies to improve blood glucose management, such as frequent monitoring of blood glucose.
In people with type 1 diabetes, their insulin-secreting cells are systematically destroyed by the body's immune system. Today, most type 1 diabetics use technologies such as glucose test strips and insulin pens to manage their blood glucose levels. These are invasive technologies where the individual must break the skin to draw blood in order to test blood sugar and inject insulin into the body.
The next wave of diabetes management devices is portable insulin pumps and continuous glucose monitors. These devices are already in use today and their use is increasing. The devices remove a significant number of pain points from current technologies. For example, the CGM, a $ 2.6 billion market in 2018, are inserted once every few weeks and provide almost continuous feedback on glucose levels. This improves glycemic monitoring and decreases the number of times an individual has to prick themselves. The artificial pancreas is one of the axes of technology: CGM and insulin pumps communicate to automatically modulate blood sugar.
To learn more about the current shifts in the technology landscape for diabetes management, please refer to the IDTechEx report: "Technologies for Diabetes Management 2019-2029: Technologies, Actors and Forecasts".
However, a more direct approach to treating type 1 diabetes is to replace beta cells. While patients can receive pancreatic islet transplants, the innovation lies in cell therapy devices. These devices enclose insulin-secreting cells in a protective pouch to protect them from attacks by the immune system. The pocket also traps cells for easy monitoring and recovery while allowing insulin to diffuse. Such a system is a significant improvement over current methods of managing diabetes. There are already several companies in this space, including ViaCyte, Sernova Corporation, Betalin Therapeutics, Semma Therapeutics and Sigilon Therapeutics.
ViaCyte and Sernova are apparently the leaders of this group of companies, both of whom have initiated at least Phase I / II clinical trials on their cell therapy devices. ViaCyte is a few years ahead of Sernova – ViaCyte already has 2-year safety results for its sub-therapeutic dose cell bag, while Sernova only began clinical trials in April. Semma Therapeutics has announced plans to launch clinical trials in 2020.
Sernova has already presented the provisional results to the International Congress of the International Pancreatic and Pancreatic Transplant Association. Lyon, France in July showed that patients with their cell therapy pocket had an 87.5% reduction in hypoglycaemic events from baseline and a weight loss of 12% of total body weight.
All this is very promising for patients with type 1 diabetes, who hopefully in the next 10 years, can see their daily lives completely transformed by pbading multiple finger tests and injections. insulin daily at occasional insulin pumps and CGM changes at a cell secreting insulin implanted. therapy apparatus.
To learn more about tissue engineering technologies such as cell encapsulation devices, please refer to the IDTechEx report: "Diabetes Management Technologies 2019-2029: Technology, Stakeholders and Forecasting ".
IDTechEx guides your strategic business decisions through its research, consulting and event products, allowing you to take advantage of emerging technologies. For more information on IDTechEx Research and Consultancy, contact [email protected] or visit www.IDTechEx.com.
To learn more about life science research available on IDTechEx, visit www.IDTechEx.com/LifeSci IDTechEx Events hosts: Healthcare Healthcare Innovations Conference 2019 Conference on 25 – or to connect with others on this topic September 26, 2019 in Cambridge, United Kingdom. Please visit www.IDTechEx.com/Cambridge.
Media contact:
Jessica Abineri
Marketing badistant
+44 (0) 1223 812300
Related Links
Other IDTechEx research on life sciences
Healthcare Sensor Innovations 2019: Point of Care Diagnostics and Monitoring
SOURCE IDTechEx
Related Links
https://www.idtechex.com
Source link
